388 related articles for article (PubMed ID: 19203902)
1. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
[TBL] [Abstract][Full Text] [Related]
2. Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Santoro MM; Bertoli A; Lorenzini P; Lazzarin A; Esposito R; Carosi G; Di Perri G; Filice G; Moroni M; Rizzardini G; Caramello P; Maserati R; Narciso P; Cargnel A; Antinori A; Perno CF;
AIDS Patient Care STDS; 2008 Jan; 22(1):7-16. PubMed ID: 18095835
[TBL] [Abstract][Full Text] [Related]
3. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study).
Di Giambenedetto S; Fabbiani M; Colafigli M; Ciccarelli N; Farina S; Sidella L; D'Avino A; Mondi A; Cingolani A; Tamburrini E; Murri R; Navarra P; Cauda R; De Luca A
J Antimicrob Chemother; 2013 Jun; 68(6):1364-72. PubMed ID: 23372058
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
5. Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Perez-Molina JA; Rubio R; Rivero A; Pasquau J; Suárez-Lozano I; Riera M; Estébanez M; Santos J; Sanz-Moreno J; Troya J; Mariño A; Antela A; Navarro J; Esteban H; Moreno S;
Lancet Infect Dis; 2015 Jul; 15(7):775-84. PubMed ID: 26062881
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Giuntini R; Martinelli C; Ricci E; Vichi F; Gianelli E; Madeddu G; Abeli C; Palvarini L; Penco G; Marconi P; Grosso C; Pellicano G; Bonfanti P; Quirino T
HIV Med; 2010 Jan; 11(1):40-5. PubMed ID: 19686438
[TBL] [Abstract][Full Text] [Related]
7. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Daar ES; Tierney C; Fischl MA; Sax PE; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Pappa KA; Woodward WC; Patterson K; Bolivar H; Benson CA; Collier AC;
Ann Intern Med; 2011 Apr; 154(7):445-56. PubMed ID: 21320923
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; DeJesus E; Bellos N; Murphy D; Sutherland-Phillips DH; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
HIV Clin Trials; 2010; 11(2):69-79. PubMed ID: 20542844
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
10. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
11. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Thiry A; McGrath D;
Lancet; 2008 Aug; 372(9639):646-55. PubMed ID: 18722869
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.
Landman R; Diallo MB; Gueye NF; Kane CT; Mboup S; Fall MB; Ndiaye B; Peytavin G; Bennai Y; Benalycherif A; Girard PM; Sow PS
AIDS Res Hum Retroviruses; 2010 May; 26(5):519-25. PubMed ID: 20455760
[TBL] [Abstract][Full Text] [Related]
14. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
Casado JL; de Los Santos I; Del Palacio M; García-Fraile L; Pérez-Elías MJ; Sanz J; Moreno S
HIV Clin Trials; 2013; 14(1):1-9. PubMed ID: 23372109
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Soriano V; García-Gasco P; Vispo E; Ruiz-Sancho A; Blanco F; Martín-Carbonero L; Rodríguez-Novoa S; Morello J; de Mendoza C; Rivas P; Barreiro P; González-Lahoz J
J Antimicrob Chemother; 2008 Jan; 61(1):200-5. PubMed ID: 17999977
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Lennox JL; Landovitz RJ; Ribaudo HJ; Ofotokun I; Na LH; Godfrey C; Kuritzkes DR; Sagar M; Brown TT; Cohn SE; McComsey GA; Aweeka F; Fichtenbaum CJ; Presti RM; Koletar SL; Haas DW; Patterson KB; Benson CA; Baugh BP; Leavitt RY; Rooney JF; Seekins D; Currier JS;
Ann Intern Med; 2014 Oct; 161(7):461-71. PubMed ID: 25285539
[TBL] [Abstract][Full Text] [Related]
17. Short-term effect of ritonavir-boosted atazanavir in hepatitis B and/or C co-infected, treatment-experienced HIV patients.
Pérez-Elías MJ; Gatell JM; Flores J; Santos J; Vera-Médez F; Clotet B; Moreno A; Pérez-Molina JA; Vendrell B; Serrano O
HIV Clin Trials; 2009; 10(4):269-75. PubMed ID: 19723614
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Baril J; Conway B; Giguère P; Ferko N; Hollmann S; Angel JB
HIV Med; 2014 May; 15(5):301-10. PubMed ID: 24314017
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy of atazanavir in treatment-naive patients].
Moreno S; Hernández B; Dronda F
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 17():9-13. PubMed ID: 20116611
[TBL] [Abstract][Full Text] [Related]
20. Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification strategy in routine clinical practice.
Santos JR; Moltó J; Llibre JM; Pérez N; Capitán ; Miranda C; Clotet B
HIV Clin Trials; 2009; 10(3):129-34. PubMed ID: 19632951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
